AAPL   366.95 (+0.78%)
MSFT   207.56 (+1.40%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
CGC   16.50 (+0.18%)
BABA   224.69 (+4.05%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.41 (+1.67%)
ACB   12.10 (-1.39%)
F   6.10 (+2.01%)
DIS   113.44 (+0.37%)
BAC   23.48 (+0.90%)
AAPL   366.95 (+0.78%)
MSFT   207.56 (+1.40%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
CGC   16.50 (+0.18%)
BABA   224.69 (+4.05%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.41 (+1.67%)
ACB   12.10 (-1.39%)
F   6.10 (+2.01%)
DIS   113.44 (+0.37%)
BAC   23.48 (+0.90%)
AAPL   366.95 (+0.78%)
MSFT   207.56 (+1.40%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
CGC   16.50 (+0.18%)
BABA   224.69 (+4.05%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.41 (+1.67%)
ACB   12.10 (-1.39%)
F   6.10 (+2.01%)
DIS   113.44 (+0.37%)
BAC   23.48 (+0.90%)
AAPL   366.95 (+0.78%)
MSFT   207.56 (+1.40%)
FB   234.72 (-1.19%)
GOOGL   1,483.64 (+2.89%)
AMZN   2,906.88 (+0.98%)
CGC   16.50 (+0.18%)
BABA   224.69 (+4.05%)
TSLA   1,205.01 (+7.63%)
AMD   52.40 (-0.34%)
T   30.41 (+1.67%)
ACB   12.10 (-1.39%)
F   6.10 (+2.01%)
DIS   113.44 (+0.37%)
BAC   23.48 (+0.90%)
Log in

NYSE:TEVATeva Pharmaceutical Industries Stock Price, Forecast & News

$11.40
-0.11 (-0.96 %)
(As of 07/2/2020 02:44 PM ET)
Add
Compare
Today's Range
$11.26
Now: $11.41
$11.88
50-Day Range
$10.97
MA: $12.20
$13.12
52-Week Range
$6.07
Now: $11.41
$13.76
Volume9.31 million shs
Average Volume9.05 million shs
Market Capitalization$12.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.65
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Read More
Teva Pharmaceutical Industries logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-3914-8171

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.89 billion
Cash Flow$3.60 per share
Book Value$13.79 per share

Profitability

Net Income$-998,000,000.00

Miscellaneous

Employees40,039
Outstanding Shares1,092,190,000
Market Cap$12.46 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

How has Teva Pharmaceutical Industries' stock been impacted by COVID-19 (Coronavirus)?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TEVA stock has increased by 26.6% and is now trading at $11.4050. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Teva Pharmaceutical Industries?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 4 sell ratings, 12 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Teva Pharmaceutical Industries.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Teva Pharmaceutical Industries.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) posted its quarterly earnings data on Thursday, May, 7th. The company reported $0.76 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.59 by $0.17. The firm earned $4.36 billion during the quarter, compared to analysts' expectations of $4.15 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.10% and a negative net margin of 4.73%. The company's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business earned $0.60 earnings per share. View Teva Pharmaceutical Industries' earnings history.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY20 earnings guidance on Thursday, May, 7th. The company provided EPS guidance of $2.30-2.55 for the period, compared to the Thomson Reuters consensus estimate of $2.44. The company issued revenue guidance of $16.6-17.0 billion, compared to the consensus revenue estimate of $16.74 billion.

What price target have analysts set for TEVA?

22 analysts have issued 12-month price targets for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they anticipate Teva Pharmaceutical Industries' share price to reach $11.50 in the next twelve months. This suggests a possible upside of 0.8% from the stock's current price. View analysts' price targets for Teva Pharmaceutical Industries.

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

News articles about TEVA stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Teva Pharmaceutical Industries.

Who are some of Teva Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Bank of America (BAC), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Cisco Systems (CSCO) and Walt Disney (DIS).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:
  • Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
  • Mr. Michael McClellan, Exec. VP & CFO (Age 48)
  • Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
  • Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $11.41.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $12.46 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.